The split proxy advisor recommendations (Egan-Jones for, Glass Lewis against) create uncertainty, but Garg's claim of majority support and the Egan-Jones endorsement provide momentum. Watch for the October 2 consent submission deadline and any settlement announcements. The 8-K filed September 8 (Item 5.02) may reveal board changes or fight results materializing.
Price Chart
Executive Summary
Founder Vishal Garg's dissident group filed definitive additional proxy soliciting materials (DFAN14A) on September 16, 2026, highlighting that Glass Lewis found 'legitimate grounds for criticism of the incumbent board' and that Egan-Jones recommended shareholders vote FOR the removal of five directors. The filing signals escalating proxy fight momentum with two proxy advisors split (Glass Lewis against, Egan-Jones for), and Garg claims majority shareholder support with a target consent submission date of October 2, 2026.
Key Financial Metrics
Key Facts
- Garg Group filed DFAN14A on September 16, 2026, seeking removal of directors Daniel Lewis, Harit Talwar, Arnaud Massenet, Bhaskar Menon, and Prabhu Narasimhan
- Egan-Jones recommended shareholders vote FOR the Garg Group's proposals, citing TSR outperformance and questioning the Board's rationale for removing Garg
- Glass Lewis found 'legitimate grounds for criticism of the incumbent board' regarding leadership transition and defensive posture, but recommended against the dissident
- Garg claims majority shareholder support (>50.1% of voting power) and has set a target date of October 2, 2026 for submission of written consents
- BETR stock returned approximately 104.5% from August 1, 2025 through August 3, 2026 under Garg's leadership, vs 25.5% for Nasdaq Composite
- The Board adopted a Rights Plan (poison pill) and pursued emergency federal injunctive relief in response to the consent solicitation
Financial Impact
Control of five of eight board seats at a company with ~$110BN in cumulative home financing originations under Garg's leadership; stock declined ~48% after Garg's August 3 CEO departure
Risk Factors
- Glass Lewis recommended against the dissident, which may influence institutional shareholders
- Board's poison pill and emergency injunctive relief could delay or complicate the consent solicitation process
- Garg's campaign lacks replacement director nominees, which Glass Lewis noted as a constraint
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DFAN14A Filing (Primary) | 0000921895-26-002560 |
| Document: 0000921895-26-002560-index-headers.html | 0000921895-26-002560 |
| Document: 0000921895-26-002560-index.html | 0000921895-26-002560 |
| Document: 0000921895-26-002560.txt | 0000921895-26-002560 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 3 | $15.58 $16.58 | ▲ +6.42% | ▲ +7.60% | $20.80 (+33.50%) |
Oct 19, 2026 8d ago | 144 | $10.53 $11.97 | ▲ +13.68% | ▲ +13.34% | $20.80 (+97.53%) |
Oct 16, 2026 10d ago | SC 13G/A | $10.53 $11.97 | ▲ +13.68% | ▲ +13.34% | $20.80 (+97.53%) |
Oct 16, 2026 11d ago | 3 | $10.53 $11.97 | ▲ +13.68% | ▲ +13.34% | $20.80 (+97.53%) |
Oct 15, 2026 12d ago | 3 | $9.95 $10.53 | ▲ +5.83% | ▲ +5.41% | $20.80 (+109.05%) |
Oct 14, 2026 13d ago | 8-K | $10.76 $9.95 | ▲ +7.53% | ▲ +6.42% | $20.80 (−93.31%) |
Oct 14, 2026 13d ago | 8-K/A | $10.76 $9.95 | ▲ +7.53% | ▲ +6.42% | $20.80 (−93.31%) |
Oct 13, 2026 14d ago | 8-K | $8.12 $10.76 | ▲ +32.51% | ▲ +32.23% | $20.80 (+156.16%) |
Oct 9, 2026 18d ago | 8-K | $9.20 $8.97 | ▲ +2.50% | ▲ +2.49% | $20.80 (−126.09%) |
Oct 9, 2026 18d ago | 8-K/A | $9.20 $8.97 | ▲ +2.50% | ▲ +2.49% | $20.80 (−126.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers